Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

(2018) Yasuto Yoneshima et al.   LUNG CANCER

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma

(2016) Yih-Leong Chang et al.   EUROPEAN JOURNAL OF CANCER

Study of pathway cross-talk interactions with NF-κB leading to its activation via ubiquitination or phosphorylation: A brief review

(2016) Sayantan Ghosh et al.   GENE

Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis

(2016) Sihua Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

(2016) Kazuki Takada et al.   Journal of Thoracic Oncology

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma

(2016) Zhengbo Song et al.   Journal of Translational Medicine

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

(2016) Yoon Jin Cha et al.   LUNG CANCER

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors

(2016) Yangwei Fan et al.   OncoTargets and Therapy

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

(2015) Kailong Lin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gain of HIF-1  under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes

(2015) Y.-H. Lee et al.   CLINICAL CANCER RESEARCH

Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade

(2015) Gaurav Goel et al.   Journal of Hematology & Oncology

Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry

(2015) Florian Kocher et al.   LUNG CANCER

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

(2015) Wendy A. Cooper et al.   LUNG CANCER

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

(2015) Patcharee Ritprajak et al.   ORAL ONCOLOGY

HIF-1α pathway: role, regulation and intervention for cancer therapy

(2015) Georgina N. Masoud et al.   Acta Pharmaceutica Sinica B

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

Hypoxia Enhances Proliferation of Human Adipose-Derived Stem Cells via HIF-1ɑ Activation

(2015) Natsuko Kakudo et al.   PLoS One

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-κB Signalling

(2014) Hai-Yu Xiong et al.   Asian Pacific Journal of Cancer Prevention

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

(2014) Chunxiao Xu et al.   CANCER CELL

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation

(2014) Miguel F. Sanmamed et al.   CANCER JOURNAL

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting of EGFR and HER2 with therapeutic antibodies and siRNA

(2014) Henri Wichmann et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

(2014) Grzegorz J. Korpanty et al.   Frontiers in Oncology

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

(2013) S. Dearden et al.   ANNALS OF ONCOLOGY

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

(2013) Jie Zou et al.   Journal of Hematology & Oncology

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment

(2013) Gang Huang et al.   PLoS One

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway

(2011) Jiao Chen et al.   IMMUNOBIOLOGY

Regulation and Function of NF-κB Transcription Factors in the Immune System

(2009) Sivakumar Vallabhapurapu et al.   Annual Review of Immunology

HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery

(2009) G. Semenza   CURRENT PHARMACEUTICAL DESIGN

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA